Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin
Autore:
Li, MF; Huang, XJ; Zhu, ZY; Wong, M; Watkins, S; Zhao, AQ; Herberman, R; Gorelik, E;
Indirizzi:
Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 st Canc, Pittsburgh, PA 15213 USA Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 Pathol, Pittsburgh, PA 15213 USA Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 l Oncol, Pittsburgh, PA 15213 USA Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 Imaging, Pittsburgh, PA 15213 USA
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 6, volume: 24, anno: 2001,
pagine: 472 - 481
SICI:
1524-9557(200111/12)24:6<472:IRA3LL>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL-MEDIATED CYTOTOXICITY; FIBROBLAST GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; ANGIOGENESIS IN-VIVO; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; UV-LIGHT; SENSITIVITY; ANGIOSTATIN; INHIBITION;
Keywords:
tumor immunogenicity; endostatin; tumor vaccination; combined antiangiogenic and immune therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Gorelik, E Univ Pittsburgh, Inst Canc, Biomed Sci Tower,Rm W954,211 Lothrop St, Pittsburgh, PA 15213 USA Univ Pittsburgh Biomed Sci Tower,Rm W954,211Lothrop St Pittsburgh PA USA 15213
Citazione:
M.F. Li et al., "Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin", J IMMUNOTH, 24(6), 2001, pp. 472-481

Abstract

The ability of the antitumor immune response to potentiate the therapeuticefficacy of the antiangiogenic agent endostatin was investigated. The antitumor effects of endostatin were tested against weakly immunogenic 3LL Lewis lung carcinoma and its highly immunogenic variant 3LL-C75. Using in vivo Matrigel assay, it was found that the recombinant endostatin produced in the authors' laboratory has a potent antiangiogenic effect. Endostatin manifested a more potent antitumor effect against highly immunogenic 3LL-C75 thanweakly immunogenic 3LL tumor, Endostatin induced regression of immunogenic3LL-C75 tumor in 40% of C57BL/6 mice, whereas partial inhibition and no regression were found in mice bearing weakly immunogenic 3LL tumor. 3LL and 3LL-C75 cells produced similar amounts of Vascular Endothelial Growth Factor, and immunohistochemical analysis revealed that endostatin treatment reduced microvessel density in both 3LL and 3LL-C75 tumors. However, infiltration of T lymphocytes was observed in 3LL-C75 but not in 3LL tumors. These results suggest that the host's immune response may potentiate the antitumor effects of antiangiogenic agents. This possibility was further supported by findings that the antitumor activity of endostatin against 3LL-C75 tumor was lower in immunodeficient than in immunocompetent mice. Stimulation of immune response against 3LL tumor by vaccination with highly immunogenic 3LL-C75 cells substantially increased the antitumor effect of endostatain, resulting in a complete and permanent regression of 3LL tumor in 50% of mice. Tumor vaccination or endostatin treatment applied separately inhibited but did not induce regression of 3LL tumor. These results suggest that the combined attack against tumor cells and the tumor vascular system using antitumorimmune mechanisms and antiangiogenic drugs can be a promising strategy forcancer treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 22:24:20